Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening
Posted on: Monday, 29 October 2007, 09:00 CDT
NOVATO, Calif., Oct. 29 /PRNewswire/ -- Diamics announced today that it has received the European CE Mark (Conformite Europeene) approval for its Pap-Map(TM) System for cervical cancer screening. The CE Mark certifies that the product has met EU health, safety and environmental requirements that ensure consumer and workplace safety. Granted in the Netherlands, the registration will allow the system to be marketed in the European Union (EU) and other countries around the world that recognize the CE Mark.
The Pap-Map System was developed to improve the effectiveness of traditional cervical cancer screening. Comprised of the Pap-Map Cervical Cancer Collector, the Pap-Map Handle and the Transfer Station, the system allows the clinician to painlessly capture 360 degrees of cervical material and transfer the cells, with their spatial orientation intact, to a slide to support localization of identified lesions in both initial diagnosis and follow-up treatments.
"This CE Mark registration is a clear milestone for Diamics as it opens the door for commercialization of the system throughout the EU and other areas to help improve the detection of cervical cancer," said Peter Gombrich, CEO, Diamics.
"This approval clears the way for the Pap-Map system to establish itself as a platform for molecular-based cervical cancer screening," said Piush Vidyarthi, Vice President of Business Development, Diamics.
Cancer of the cervix is the second most commonly diagnosed cancer in women worldwide. Approximately 500,000 new cases are diagnosed each year, 80% of which occur in developing countries. It is estimated that of the more than 2.5 billion females worldwide who are eligible for cervical cancer testing only approximately 6%, or 160 million, are screened routinely.
About Diamics, Inc.
Diamics Inc. is a privately owned medical device and diagnostics company located in the San Francisco Bay Area. The company is committed to developing, manufacturing, and marketing cost effective, molecular-based cancer screening and diagnostic systems that will increase long-term cancer survival rates through early detection. Diamics' management team has an extensive track record of success in the medical device and diagnostics industries. The company's mission is twofold: to help medical personnel worldwide improve the lives of the people they treat and to generate a return on investment for its shareholders. For more information, please visit http://www.diamics.com/.
Diamics, Inc.
CONTACT: Peter Gombrich of Diamics, +1-415-883-2972,pgombrich@diamics.com; or Jennifer Larson, +1-415-409-2729,jlarson@labfive.com, for Diamics
Web site: http://www.diamics.com/
Source: PRNewswire
Related Articles
- New Lung Cancer Staging System Found
- BSD Medical's Premier Cancer Treatment System Can Now Treat Children's Cancers
- BSD-2000 Cancer Treatment System Purchased By Nanchong Hospital in China
- Switzerland Receives First Hyperthermia Cancer Treatment System From BSD Medical
- BSD-2000 Cancer Treatment System Acquired in Taiyuan City, China
- Modern Technology Corp. Subsidiary Insight Medical Group Releases Business Plan for AnuCyte Cancer Detection System
- BSD Medical Presents Cutting-Edge Cancer Treatment Systems at New York Oncology Congress
- BSD Medical Applies for FDA Approval of the BSD-2000 Cancer Treatment System
- Deaconess Hospital Installs Revolutionary Cancer Treatment System - 3-D Imaging Allows More Accurate Identification and Treatment of Cancerous Tumors
 |
 |
User Comments (0)
RSS Feeds